Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2515837 | 0.86 | TAAR1 (0.54) | TAAR1HTR2AIDO1MAOAMAOB | |
| SCHEMBL7007233 | 0.80 | TAAR1 (0.48) | TAAR1HTR2AIDO1MAOAMAOB | |
| SCHEMBL11108664 | 0.78 | TAAR1 (0.47) | TAAR1HTR2AIDO1MAOAMAOB | |
| SCHEMBL6542140 | 0.78 | TAAR1 (0.46) | TAAR1IDO1MAOB | |
| SCHEMBL10500468 | 0.77 | CA1 (0.45) | TAAR1HTR2AIDO1MAOAMAOB | |
| SCHEMBL16898703 | 0.77 | TAAR1 (0.61) | TAAR1HTR2AIDO1MAOAMAOB | |
| SCHEMBL8417751 | 0.77 | TAAR1 (0.45) | TAAR1HTR2AIDO1MAOAMAOB | |
| SCHEMBL1680408 | 0.77 | TAAR1 (0.45) | TAAR1HTR2AIDO1MAOAMAOB | |
| SCHEMBL4670222 | 0.77 | MEN1 (0.46) | TAAR1HTR2AIDO1MAOAMAOB | |
| SCHEMBL6541809 | 0.75 | TAAR1 (0.53) | TAAR1IDO1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1052982-A4 | AMINOTETRALINS AS 5-HT 1D$g(a)? AGONISTS | LILLY CO ELI (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20020065312-A1 | Aminotetralins as 5-HT1Dalpha agonists | SCHAUS JOHN M (US) | 2002-05-30 | — | — | US | disclosed |
| US-6355674-B1 | PSYCHOLOGICAL DISORDERS; ANTISEROTONINE AGENTS | ELI LILLY AND COMPANY | 2002-03-12 | — | — | US | disclosed |
| EP-1052982-A1 | AMINOTETRALINS AS 5-HT 1D$g(a)? AGONISTS | ELI LILLY AND COMPANY (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1998048786-A1 | AMINOTETRALINS AS 5-HT1Dα AGONISTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065312-A1 | Aminotetralins as 5-HT1Dalpha agonists | HTR1D, HTR1A, HTR1E | TAAR1 39/4885HTR2A 11/4885IDO1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.